AbbVie Inc. Overview
Pro stress-test →AbbVie is a global biopharmaceutical company that discovers, develops, and commercializes advanced therapies addressing some of the world's greatest health challenges. In 2025, the company delivered record net sales in the second full year following the U.S. Humira loss of exclusivity, underscoring the strength of its diversified growth platform.
Strategic Profile
Pro stress-test →AbbVie focuses on key therapeutic areas including immunology, neuroscience and oncology, with products and services in its Allergan Aesthetics portfolio. The company has strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). In January 2026, AbbVie struck a deal with the Trump administration to invest $100 billion in its US operations over the next 10 years and lower Medicaid prices, with the administration exempting AbbVie from tariffs and future pricing mandates.
Competitive Landscape
Pro stress-test →Biogen, Gilead Sciences, Eli Lilly, Amgen, and Roche are key competitors. AbbVie competes in large immunology and oncology markets where multiple players offer competing therapies, though its portfolio diversification and post-Humira transition success provide competitive advantages.
Industry Context
AbbVie Inc. operates in Biopharmaceuticals/Specialty Pharmaceuticals.
Key facts
Founded: 2012 · Headquarters: North Chicago, US · Employees: 56,000 · Revenue: $56.3B · Market cap: $338B